B

BiohacksAI

Evidence-Based Biohacking

Patent Pending

Erlotinib

0 PubMed studies analyzed

Similar Compounds by Shared Targets

The following compounds share molecular targets with Erlotinib, based on binding affinity data from BindingDB and ChEMBL. Sorted by shared target overlap.

canertinib
73 shared targets
gefitinib
60 shared targets
vandetanib
64 shared targets
cediranib
51 shared targets
pelitinib
56 shared targets
foretinib
79 shared targets
r
89 shared targets
pazopanib
53 shared targets
doramapimod
45 shared targets
fedratinib
88 shared targets
Loading evidence profile...

This evidence profile for Erlotinib is generated deterministically from 0 PubMed-indexed studies. All data is corpus-verified with Merkle proofs. BiohacksAI does not provide medical advice. Always consult a healthcare professional before starting any supplement regimen.

Data source: PubMed/MEDLINE (NLM). Corpus version: v20260227-01. Patent pending (EVE-PAT-2026-001). © 2026 Organiq Sweden AB.